Weil GJ, et al. - Whether ivermectin with diethylcarbamazine and albendazole [IDA] and diethylcarbamazine plus albendazole [DA] are safe for use as a mass drug administration (MDA) regimen in patients with lymphatic filariasis (LF) was investigated in a variety of endemic settings via large community studies conducted in five countries: Papua New Guinea, Indonesia, India, Haiti, and Fiji. The enrolled individuals were 26,836, including 13,535 females and 13,300 males. A single oral dose of IDA (ivermectin, 200 μg/kg; diethylcarbamazine, 6 mg/kg; plus albendazole, a fixed dose of 400 mg) or DA alone was administered to the participants. Findings revealed good tolerability of IDA in LF-endemic populations. No significant difference was observed between IDA or DA treatment in terms of posttreatment adverse event rates and severity. In this study, the safety of IDA was recommended to be equal to that of DA, when it comes to its use as a MDA regimen for LF removal in areas that currently receive DA.